Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Downloads of FPMAJ’s E-Labeling App on Track to Target 50,000 as Legal Enforcement Approaches
With new e-labeling regulations set to be enforced next month, a “GS1” barcode-reading app to access electronic prescribing information developed by the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) had racked up more than 45,000 downloads as of July…
To read the full story
Related Article
- Industry Group Rolls Out Barcode Reader App for E-Labeling
April 8, 2021
- Industry Group Poised for Pilot Rollout of E-Labeling App in April, Looks to Sales Reps for Popularization
March 26, 2021
- MHLW Formally Adopts GS1 Codes for Electronic Package Inserts; Rule to Take Effect August 1
February 25, 2021
- With PMD Law Amended, Japan Pharma Industry Revs Up Work for Electronic Distribution of Prescribing Info
December 5, 2019
ORGANIZATION
- JMA’s Ezawa Calls for “National Debate” on Drug Policy
March 31, 2026
- BCG’s Takeda Questions Conditional Pricing for Regenerative Medicines
March 25, 2026
- Industry Groups Push Mindset Shift to Streamline Japan’s Clinical Trials
March 24, 2026
- FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
March 24, 2026
- FPMAJ Calls for Drug Price Hike, End to Off-Year Revisions in FY2026 Plan
March 23, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…